Regeneron's Otarmeni Approval Sets New Benchmark for Gene Therapy

Benitec Biopharma Inc. Shares Promising BB-301 Clinical Results at ASGCT 2026 We came across an important clinical update from Benitec Biopharma Inc. that highlights meaningful progress in rare disease treatment. The company announced interim Phase 1b/2a results for its gene therapy candidate BB-301, targeting Oculopharyngeal Muscular Dystrophy (OPMD), a condition with no approved therapies and affecting nearly 15,000 patients globally. The therapy is specifically addressing severe dysphagia, a life-threatening complication impacting 97% of patients. Key highlights from the study include: • 12-month follow-up results from the first 4 Cohort 1 patients • 24-month durability data from the first patient • Early positive signals from Cohort 2 BB-301 stands out as the only clinical-stage therapy currently in development for OPMD-related dysphagia. Built on a novel “Silence and Replace” platform, it combines RNA interference with gene therapy to silence the mutated gene while restoring functional protein expression. The data will be presented at the American Society of Gene and Cell Therapy Annual Meeting 2026, where CEO Jerel A. Banks, M.D., Ph.D. will share insights on long-term safety and durable efficacy; signaling growing confidence in this innovative approach. With Orphan Drug and Fast Track designations from the FDA and EMA, BB-301 is positioning itself as a potential breakthrough in rare genetic disease treatment. We believe advancements like these are redefining the future of gene therapy and bringing new hope to underserved patient populations. Follow us for more real-time healthcare and biotech updates shaping the future. Submit your latest company news/updates/announcements/events, and we’ll feature it on our official LinkedIn page (Towards Healthcare Research & Consulting) free of charge. DM us or Contact us for further process: https://lnkd.in/dNNTvgwa #HealthcareResearch #BiotechNews #GeneTherapy #RareDiseases #ClinicalTrials #BenitecBiopharma #ASGCT2026 #OPMD #DrugDevelopment #Biopharma #InnovationInHealthcare

💙 Dilated Cardiomyopathy Market Shows Promising Growth Amid Advances in Gene Therapy and Precision Cardiology | DelveInsight The #DilatedCardiomyopathyMarket is expected to witness notable growth in the coming years, driven by increasing prevalence of heart failure disorders, advancements in genetic testing, and the emergence of novel disease-modifying therapies. According to DelveInsight, the expanding therapeutic pipeline and improved diagnosis of inherited cardiomyopathies are expected to reshape the treatment landscape across the 7MM. 📌 Recent News – May 2026 🔹 In a major development, Affinia Therapeutics continued to advance its investigational gene therapy #AFTX201 for #BAG3-associated DCM. The company recently received FDA Fast Track designation, and its Phase I/II UPBEAT trial is moving forward in North America, marking a significant milestone for gene therapy in inherited dilated cardiomyopathy. 🔹 Another key trend in 2026 is the growing focus on genetic cardiomyopathy clinical trials. Several companies are expanding research into gene replacement and RNA-based therapies for inherited forms of DCM, signaling a shift from symptomatic management to therapies that target the underlying genetic cause of disease. Major companies active in the competitive landscape include Affinia Therapeutics, Rocket Pharmaceuticals, Bristol Myers Squibb, Pfizer, and emerging cardiovascular biotech innovators. 📈 The #DCMmarket is poised for meaningful transformation, offering new opportunities for stakeholders in cardiovascular therapeutics @ https://lnkd.in/gZbCEPVf #DilatedCardiomyopathy #Cardiomyopathy #HeartFailure #GeneTherapy #RareDiseases #Cardiology #Biotech #Pharma #ClinicalTrials #PrecisionMedicine #Healthcare #MarketResearch #DrugDevelopment #DelveInsight #Cardiovascular

The cell and gene therapy field is navigating a more complex regulatory moment. At last week’s Meeting on the Med, Alliance for Regenerative Medicine's Tim Hunt reported that the FDA rejection rate for cell and gene therapies rose from 18% between 2020 and 2024 to 38% over the following 15 months. That shift has understandably raised concerns across the sector, especially for developers working in rare and ultra-rare diseases where trial design, patient recruitment, and long-term follow-up are inherently difficult. But the current landscape cannot solely be attributed to regulatory caution. Some programs are reaching late-stage development with promising early signals, but those signals may not always be sufficiently tied to clinically meaningful outcomes. Recent FDA decisions suggest the question is not always whether a therapy shows biological activity, but whether the endpoint, biomarker strategy, and use of external controls are strong enough to demonstrate meaningful clinical benefit. Biomarker selection, endpoint validation, external controls, human relevance of preclinical models, and durability of response are all becoming more central to how regulatory packages are evaluated. For developers, early alignment with regulators remains essential, but so does building an evidence package that can withstand scrutiny as programs advance. That means thinking earlier about what endpoints truly demonstrate patient benefit, whether biomarkers are clinically validated, how external controls are justified, and where human-relevant data can reduce uncertainty before pivotal development. As cell and gene therapies continue to move into more complex indications and patient populations, the field requires both regulatory flexibility and evidentiary rigor. The next phase of progress will depend on how well developers can bring those two priorities together and create a strong foundation for innovation. #cellandgenetherapy #MeetingontheMed #advancedtherapies

Breaking news! The FDA approval of Regeneron Pharmaceuticals’s gene therapy for a rare form of inherited deafness marks a meaningful step in the evolution of precision medicine. The treatment targets mutations in the OTOF gene, a condition that affects a very small number of newborns each year, and works by delivering a functional copy of the gene directly into the inner ear. In clinical studies, children who received the therapy showed measurable improvements in their ability to detect and respond to sound. For families, this translates into something deeply personal. The possibility of a child hearing voices, reacting to their environment, and experiencing sound in ways that were previously not possible. At the same time, the scope of this advancement remains limited. The therapy is designed for a specific and rare genetic cause of hearing loss, meaning only a small group of patients will be eligible. It also requires a highly specialized surgical procedure to deliver the treatment into the cochlea, and as with many gene therapies, questions remain about long term durability, safety, and how outcomes will hold up outside of controlled clinical settings. While the therapy has been made available at no cost in the United States, broader considerations around scalability, access, and how similar treatments may be funded in the future remain important factors. Taken together, this approval reflects a broader shift from managing conditions to addressing them at their genetic root. It highlights both the promise and the complexity of emerging therapies, raising important questions about access, long-term impact, and how healthcare systems will adapt. While not a universal solution, it represents a significant step forward, with its ultimate impact depending on how effectively it can be translated into real world care. #ClinicalTrials #ClinicalInnovation #DrugDevelopment #MedicalAdvancements #ClinicalInsights #HealthcareInnovation #PatientCareResearch #ClinicalExcellence #FutureOfMedicine #ClinicalResearch #MedicalResearch #PharmaIndustry #DrugDevelopment #ClinicalDevelopment #ResearchAndDevelopment #LifeSciences #OncologyResearch #Breastcancer

𝗕𝗥𝗘𝗔𝗞𝗜𝗡𝗚 𝗡𝗘𝗪𝗦: Two Biotech Approvals in One Day👇 Over the last 24 hours, AstraZeneca and Krystal Biotech have secured important regulatory approvals in cardiovascular medicine and gene therapy. ✅ Baxfendy® (baxdrostat) – AstraZeneca The FDA has approved Baxfendy as the first and only aldosterone synthase inhibitor for adults with uncontrolled hypertension in combination with other antihypertensive medications. ✅ VYJUVEK® (beremagene geperpavec-svdt) – Krystal Biotech The UK MHRA has approved VYJUVEK for the treatment of dystrophic epidermolysis bullosa (DEB) from birth in patients with COL7A1 mutations. 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: ❤️ Baxfendy First-in-class aldosterone synthase inhibitor (ASI) Achieved ~10 mmHg placebo-adjusted systolic BP reduction in Phase III Potential new option for millions with resistant or uncontrolled hypertension 🧬 VYJUVEK -First genetic medicine approved in the UK for DEB - Redosable topical gene therapy targeting the root cause of disease - Flexible at-home or healthcare-setting administration Congrats to AstraZeneca and Krystal Biotech for advancing innovation in cardiovascular medicine and genetic therapies! #cardiology #genetherapy #biotech #cellandgenetherapy #CGTweekly

Great news to DMD patients. A very long and trecerous way. In this case Genomics run supreme as etiology and as treatment

Finally, a treatment for DMD that obviously works in Phase 3 clinical trials. A very good day for DMD patients and accolades to Regenxbio. After more than 15 years of Sarepta news, filled with unimpressive data, ambiguous anecdotes, and supported by FDA favoritism.... finally, Regenxbio has a gene therapy that shows clear difference in microdystrophin production, ambulatory enhancement and results that exceeded expectations.... what's not to like? Average levels of gene expressed truncated dystrophin protein at 71% after 12 weeks. For ambulatory boys, 3-fold higher of the microdystrophin RGX-202 than Sarepta Elvidys. Safety profiles revealed only one liver injury case for RGX-202 (3%), compared to 40% for patients treated with Elevidys. As for real life outcome : " Regenxbio has also shown a strong correlation between microdystrophin expression and positive physical outcomes. Nine boys treated with RGX-202 posted higher scores on multiple measures of muscle function, like time to stand and time to run and walk, compared to what would be expected based on the disease’s natural history. This correlation hasn’t been seen with Elevidys, which Pakola said likely comes down to the fact that not all microdystrophin is created equally." Massive congratulations to Regenxbio - and best wishes sailing to approval thru the FDA. Fierce Biotech article here: https://lnkd.in/eT28ivig

Intellia Therapeutics, Inc. just reported Phase 3 data showing an 87% reduction in hereditary angioedema attacks with a single CRISPR infusion and immediately filed for FDA approval. This is the first Phase 3 readout for any in vivo gene editing therapy in history. Who owns the best one-time gene-editing platform to go after chronic diseases currently managed with lifetime therapy? More to come for this week's brief https://lnkd.in/eSsSCXyt

💙 Access. Retention. FDA Approval. This Is What Patient-First Trials Look Like. mdgroup partnered with Rocket Pharmaceuticals to support families participating in a complex rare disease study, removing barriers through international travel coordination, accommodation, financial support and hybrid follow-up care at home. At a glance: ✔ Global patient support across 5+ countries ✔ Hybrid trial delivery across site and home ✔ 0 missed visits across treatment and follow-up ✔ Up to 9 months’ relocation support per family ✔ Up to 15 years of ongoing patient support ✔ FDA approval of gene therapy Read the full case study here: https://bit.ly/48ZlI0l #ClinicalTrials #RareDisease #PatientCare

𝐎𝐩𝐮𝐬 𝐆𝐞𝐧𝐞𝐭𝐢𝐜𝐬 announced that its investigational LCA5 gene therapy, OPGx-LCA5, has been accepted into the FDA’s Rare Disease Evidence Principles (RDEP) program, supporting regulatory alignment for a potential pivotal Phase 3 pathway in Leber congenital amaurosis type 5, an ultra-rare inherited retinal disease. Key Highlights 👁️ OPGx-LCA5 targets LCA5, a severe inherited retinal disease that can cause early-onset vision loss and childhood blindness 🧬 AAV8-based gene therapy designed to deliver a functional LCA5 gene to the outer retina ⚖️ FDA RDEP acceptance supports early and ongoing alignment on clinical trial design and evidence generation 🏥 Phase 1/2 trial ongoing at the University of Pennsylvania 📊 Pediatric data showed large gains in cone-mediated vision ⏳ Adult cohort demonstrated durable improvements in cone sensitivity and visual function out to 18 months ✅ Well tolerated to date, with no ocular serious adverse events or dose-limiting toxicities reported 🏷️ Also received FDA Rare Pediatric Disease, Orphan Drug, and RMAT designations This case highlights a growing regulatory trend in ultra-rare gene therapy: flexible evidence strategies, early FDA engagement, and clinically meaningful outcomes from small patient populations may become increasingly important for advancing AAV therapies toward approval. 🔔𝐅𝐨𝐥𝐥𝐨𝐰 𝐔𝐬 𝐨𝐧 𝐋𝐢𝐧𝐤𝐞𝐝𝐢𝐧 & 𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐞 𝐭𝐨 𝐎𝐮𝐫 𝐍𝐞𝐰𝐬𝐥𝐞𝐭𝐭𝐞𝐫 𝐟𝐨𝐫 𝐖𝐞𝐞𝐤𝐥𝐲 𝐂𝐆𝐓 𝐔𝐩𝐝𝐚𝐭𝐞𝐬: https://lnkd.in/eS-3XyZ3 #GeneTherapy #AAV #InheritedRetinalDisease #RareDisease #LCA #Ophthalmology #FDA #Biotech #CellAndGeneTherapy #ClinicalDevelopment https://lnkd.in/eTfEnr-4